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ABSTRACT
OBJECTIVE
To evaluate the joint association of sodium and
potassium urinary excretion (as surrogate measures
of intake) with cardiovascular events and mortality,
in the context of current World Health Organization
recommendations for daily intake (<2.0 g sodium,
>3.5 g potassium) in adults.
DESIGN
International prospective cohort study.
SETTING
18 high, middle, and low income countries, sampled
from urban and rural communities.
PARTICIPANTS
103 570 people who provided morning fasting urine
samples.
MAIN OUTCOME MEASURES
Association of estimated 24 hour urinary sodium
and potassium excretion (surrogates for intake)
with all cause mortality and major cardiovascular
events, using multivariable Cox regression. A six
category variable for joint sodium and potassium

WHAT IS ALREADY KNOWN ON THIS TOPIC
Dietary guidelines recommend sodium restriction but increased potassium
intake (WHO recommends <2.0 g/day and >3.5 g/day, respectively)
Studies evaluation the association of sodium intake have reported inconsistent
findings, but many report a J-shaped association, while those evaluating
potassium intake generally report a linear reduction in mortality with increasing
potassium intake
Most observational studies have reported on the effects of sodium and
potassium intake separately, although some have reported on the association of
sodium:potassium ratio with clinical outcomes

WHAT THIS STUDY ADDS
The study findings question the feasibility of the WHO simultaneous target of
low sodium intake (<2 g/day) with high potassium intake (>3.5 g/day), which was
consumed by a very low proportion of the population.
The combination of moderate sodium intake (3-5 g/day) with higher potassium
intake was associated with the lowest risk of mortality and cardiovascular events
The J-shaped association of sodium intake with mortality and cardiovascular
events does not lend support to the current WHO recommendation to
consume low sodium diets (<2.0 g/day), and it also argues against use of the
sodium:potassium ratio
the bmj | BMJ 2019;364:l772 | doi: 10.1136/bmj.l772

was generated: sodium excretion (low (<3 g/day),
moderate (3-5 g/day), and high (>5 g/day) sodium
intakes) by potassium excretion (greater/equal or less
than median 2.1 g/day).
RESULTS
Mean estimated sodium and potassium urinary
excretion were 4.93 g/day and 2.12 g/day,
respectively. After a median follow-up of 8.2 years,
7884 (6.1%) participants had died or experienced a
major cardiovascular event. Increasing urinary sodium
excretion was positively associated with increasing
potassium excretion (unadjusted r=0.34), and only
0.002% had a concomitant urinary excretion of
<2.0 g/day of sodium and >3.5 g/day of potassium.
A J-shaped association was observed of sodium
excretion and inverse association of potassium
excretion with death and cardiovascular events. For
joint sodium and potassium excretion categories,
the lowest risk of death and cardiovascular events
occurred in the group with moderate sodium excretion
(3-5 g/day) and higher potassium excretion (21.9%
of cohort). Compared with this reference group, the
combinations of low potassium with low sodium
excretion (hazard ratio 1.23, 1.11 to 1.37; 7.4%
of cohort) and low potassium with high sodium
excretion (1.21, 1.11 to 1.32; 13.8% of cohort)
were associated with the highest risk, followed by
low sodium excretion (1.19, 1.02 to 1.38; 3.3% of
cohort) and high sodium excretion (1.10, 1.02 to
1.18; 29.6% of cohort) among those with potassium
excretion greater than the median. Higher potassium
excretion attenuated the increased cardiovascular
risk associated with high sodium excretion (P for
interaction=0.007).
CONCLUSIONS
These findings suggest that the simultaneous target
of low sodium intake (<2 g/day) with high potassium
intake (>3.5 g/day) is extremely uncommon. Combined
moderate sodium intake (3-5 g/day) with high
potassium intake is associated with the lowest risk of
mortality and cardiovascular events.

Introduction
Consumption of sodium and potassium is essential
to health, as neither are produced endogenously
and both are necessary for critical physiological
processes.1-3 Maintaining homeostasis requires a
1
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Methods
Study population
The PURE Study is a large scale epidemiological cohort
study that has enrolled people (aged 35 to 70 years)
residing in 628 urban and rural communities in low,
middle, and high income countries (Bangladesh,
2

India, Pakistan, Zimbabwe, Argentina, Brazil, Chile,
Malaysia, Poland, South Africa, Turkey, China,
Colombia, Iran, Canada, Sweden, Palestinian territories
occupied by Israel, and United Arab Emirates).27-29
The supplementary appendix describes the selection
of participants. Recruitment began in January 2003.
Participants provided written informed consent. For
the current analysis, we included 103 570 participants
from 18 countries who collected early morning fasting
urine samples suitable for analysis, of which 103 200
(99.6%) had follow-up information available (95%
completed at least one follow-up visit). The Population
Health Research Institute of Hamilton Health Sciences,
Ontario, Canada coordinated the study.

Exposure assessments
A morning fasting midstream urine sample, collected
from each participant, was frozen at −20ºC to −70ºC
and shipped to a central laboratory in Canada, China,
India, or Turkey. The samples were shipped at ambient
temperature using the STP 250 ambient specimen
shipping box (see supplementary appendix for a
description of the methods used for performing urinary
analyses). We used the Kawasaki formula to estimate
24 hour urinary sodium and potassium excretion from
a fasting morning sample, and these estimates have
been validated previously versus measured with 24
hour urine collection.30 31 An international validation
study reported an intraclass correlation of Kawasaki
formula to actual 24 hour urine collections of 0.71.31
Therefore, we used the estimates derived from fasting
morning urine as surrogates for sodium and potassium
intake in the study. (The supplementary appendix
provides summary details of validation of this
approach.)
Ascertainment of outcomes
Standardised case report forms were used to capture
major cardiovascular events (myocardial infarction,
stroke, and heart failure), cancer, and death at followup, which were adjudicated using standardised
definitions.32 For the current analysis, we included all
adjudicated outcome events in the PURE database up to
September 2017. The primary composite outcome was
all cause mortality or myocardial infarction or stroke
or heart failure. Secondary outcomes were individual
components of the primary composite outcome, and
new diagnosis of cancer on follow-up.
Ascertainment of covariates
All participants completed baseline standardised
questionnaires, which included detailed information
on age, sex, lifestyle risk factors (eg, smoking, diet,
physical activity, alcohol intake), comorbidities (eg,
history of diabetes, hypertension, cardiovascular
disease), physical measurements (blood pressure,
heart rate, body mass index (BMI), waist:hip ratio),
and laboratory measurement of lipoproteins (88%).
A modified alternative healthy eating index (mAHEI)
score was used to measure overall diet quality, with
higher scores indicating a healthier diet.33
doi: 10.1136/bmj.l772 | BMJ 2019;364:l772 | the bmj
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mutual interdependence of sodium and potassium,
meaning that their relation with health is necessarily
linked.1-3 Despite these fundamental physiological
considerations, current public health policy adopts
markedly opposing guidance for sodium and
potassium intake, with the World Health Organization
recommending an extremely low sodium intake (<2 g/
day, whereas the current average intake is about 4 g/
day) but high potassium intake (>3.5 g/day, whereas
the average intake is about 2 g/day) in the entire adult
population.4-6 International data on the percentage
of people with very low intakes of sodium and
simultaneously high potassium intakes7 and the joint
effects on health outcomes from large international
epidemiological studies are limited.4 5 8 9
Current public health policy on targets for sodium
intake is based primarily on small, and mostly
short term, clinical trials evaluating the relation of
changes in sodium and potassium intake with blood
pressure.4 8 Although clinical trials have reported
a decrease in blood pressure with a reduction in
sodium intake,8 many prospective cohort studies
have reported a J-shaped association of sodium intake
and cardiovascular disease or mortality,10-16 with an
increased risk emerging at sodium intakes <2.7 g/
day and >5 g/day.10 The increased cardiovascular
risk associated with high sodium intake seems to
be especially in those with hypertension,17 whereas
the increased risk associated with low sodium
intake might be mediated through activation of
physiological systems to conserve sodium (eg, reninangiotensin-aldosterone system).18 In contrast, the
association of potassium intake with blood pressure
and cardiovascular disease is consistent, with a linear
reduction in blood pressure and cardiovascular risk
with increasing potassium intake reported in most
studies.9 Some epidemiological studies report an
interactive association of sodium and potassium
intake with blood pressure, and other studies report
use of sodium:potassium ratios for predicting risk of
cardiovascular events and mortality.19-25 Whether
a potential modifying effect of increased potassium
intake is directly causal or simply a marker of improved
diet quality,26 as diets rich in fruit and vegetables
(which are associated with lower cardiovascular risk)
are high in potassium, is uncertain.
In the Prospective Urban Rural Epidemiological
(PURE) Study, we have previously reported on
the intermediate term (3.7 years of follow-up)16 17
association of sodium and potassium intake with
mortality and cardiovascular events. In the current
analyses, we further explore the association of sodium
and potassium intake with death and cardiovascular
disease in extended follow-up (eight years).
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a piecewise linear function of sodium excretion; two
connected lines above and below the median sodium
excretion with different slopes could interact with
the potassium and mAHEI subgroups. We completed
an analysis of “usual” sodium intake, based on
repeated measurement in 494 participants, employing
methodology used in previous publications.25
To minimise the potential for reverse causation,
we conducted sensitivity analyses that excluded
participants with a final follow-up or outcome event
within the first three years of baseline. To assess the
changes in hazard for the primary outcome with
simultaneous changes in sodium and potassium
excretion, the hazard ratio was modelled using a
two dimensional natural cubic spline. For each of
sodium and potassium, two knot points were selected
at the tertiles of the variable’s sample distribution.
This resulted in a grid of four knot points on a two
dimensional (sodium and potassium) spline surface.
The Cox proportional hazard model then included
(along with other covariates) natural cubic spline
variables for both sodium and potassium separately
and for interaction terms between these spline
variables. To visualise the two dimensional change
in hazard, and the putative interaction effect between
sodium and potassium, estimated hazard ratios were
plotted for each observed pair sodium and potassium
values in the analysis dataset (a heat map). The
reference for plotted hazard ratios was the hazard at
the median levels of sodium (4.70 g) and potassium
(2.1 g).
All analyses were conducted using R Version 3.4.4
(R Foundation for Statistical Computing, Vienna,
Austria).

Patient and public involvement
No patients were involved in setting the research
question or outcome measures, or in the design and
implementation of the study.
Results
In total, 103 570 participants were included, of whom
41.8% were from China. In the overall population,
mean estimated 24 hour sodium excretion was 4.9
g and mean estimated potassium excretion 2.1 g.
(see supplementary table 1) After a median duration
of 8.2 years (interquartile range 6.0-9.4) there were
4524 deaths, 4889 with a major cardiovascular event
(1893 myocardial infarctions, 2526 strokes, 534 heart
failure, and 1293 cardiovascular deaths), and 7884
had either a cardiovascular event or died, and 3263
had a diagnosis of cancer.
Mortality and cardiovascular events
Estimated sodium excretion
Compared with estimated sodium excretion of 4.00
to 4.99 g/day (the reference group), higher estimated
sodium excretion (>7 g/day) was associated with
a greater risk of the primary composite outcome
(hazard ratio 1.23, 95% confidence interval 1.12
to 1.34), all cause mortality (1.36, 1.20 to 1.53),
3
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Statistical analyses
Baseline differences in characteristics between study
participants in different categories of estimated
sodium and potassium excretion have been reported
previously (see supplementary appendix).25 Restricted
cubic spline plots were used to explore the shape of
association between estimated sodium and potassium
excretion and outcomes, fitting a restricted cubic
spline function with four knots (5th, 35th, 65th,
and 95th centiles).34 Our primary outcome measure
was the composite of all cause mortality and major
cardiovascular events (cardiovascular death, stroke,
myocardial infarction, and heart failure). Secondary
outcomes included individual components of the
primary outcome.
Based on our restricted cubic spline plots for
the primary outcome, and the results of previous
analyses,13 16 we selected 4.00 to 4.99 g/day as the
reference category for sodium excretion and <1.5 g/
day for potassium excretion. We modelled the time
to event outcome using multivariable Cox regression
proportional hazards analysis with mixed effect
(centre included as a random effect variable to
account for clustering by research site) to determine
the association between estimated urinary sodium
and potassium excretion and outcomes, using three
sequential models. Model 1 (primary model) adjusted
for age (included as spline function), sex, education,
current and former alcohol intake (units weekly),
diabetes mellitus, BMI, physical activity, history of
cardiovascular events, use of cardiovascular drugs
(blood pressure lowering, statins, or antidiabetics),
history of tuberculosis, cancer, HIV, and current
and former smoking, which constituted our
primary multivariable model (with an additional
model that included low density lipoprotein (LDL)
cholesterol:high density lipoprotein (HDL) cholesterol
ratio). Model 2 also included caloric intake, estimated
potassium (or sodium) excretion, waist:hip ratio, and
modified mAHEI. Model 3 also included history of
hypertension, and baseline systolic and diastolic blood
pressure and heart rate, which are in the putative
causal pathway. We performed an analysis of the
combined effects of sodium and potassium, in which
we generated six categories for sodium excretion (low
(<3 g/day), moderate (3-5 g/day), and high (>5 g/day)),
and potassium excretion above and below the median
(2.1 g/day). Three categories were selected for sodium
excretion, as the estimated association was J-shaped,
whereas two categories were selected for potassium
excretion, as the association was linear in analyses.
We also completed a stratified subgroup analysis of the
association between sodium excretion and outcomes,
stratified by groups of urinary potassium excretion and
mAHEI divided at the tertiles. We tested for interactions
between sodium excretion and potassium excretion
and between sodium excretion and mAHEI score. As
the association of sodium excretion and composite
outcome was non-linear, we tested for interaction
above and below median sodium excretion (ie, four
tests for interaction), modelling the log hazard ratio as

RESEARCH

Estimated potassium excretion

Compared with estimated potassium excretion of
<1.5 g/day, higher estimated potassium excretion
was associated with a lower risk of mortality and
cardiovascular events (0.83, 0.73 to 0.94 for >3 g/day)
on multivariable analysis (fig 2, supplementary table
3). This associated reduction in hazard was greater
for mortality risk (0.71, 0.60 to 0.85) than for major
cardiovascular events (0.87, 0.75 to 1.02). No apparent
association was found between potassium excretion
and cancer or cancer mortality (see supplementary
table 3).

Combined sodium and potassium excretion

Table 2 shows the association of sodium excretion
with the primary composite outcome, categorised by
joint sodium and potassium excretion (six categories).
The lowest risk of death and cardiovascular events
occurred in the group with moderate sodium excretion
(3-5 g/day) and higher potassium excretion (21.9%
of cohort). Compared with this reference group, the
combinations of low potassium with low sodium

excretion (hazard ratio 1.23, 95% confidence interval
1.11 to 1.37; 7.4% of cohort) and low potassium with
high sodium excretion (1.21, 1.11 to 1.32; 13.8% of
cohort) were associated with the highest risk, followed
by high sodium excretion (1.10, 1.02 to 1.18 (29.6% of
cohort)) and low sodium excretion (1.19, 1.02 to 1.38;
3.3% of cohort)) among those with potassium excretion
above the median. Moderate sodium excretion with low
potassium excretion was associated with an increased
risk of the primary outcome (1.10, 1.01 to 1.19; 24.0%
of cohort), compared with reference. Few participants
(0.002%) had both very low sodium excretion (<2 g/
day) and high potassium excretion (>3.5 g/day)—a
target recommended by nutrition guidelines—so
that the risk in this subgroup could not be estimated
reliably (0.2% for potassium >2.63 g/day, assuming
that about 75% of potassium is excreted in the urine,35
and sodium excretion <2.3 g/day). Figure 3 reports
results of a heat map that combines multivariable
cubic splines of the association of both sodium
excretion and potassium excretion with the primary
outcome, with median excretion as reference category.
Table 3 and figure 4 show a stratified analysis by thirds
of potassium excretion, supporting a lower relative risk
associated with higher sodium excretion among those
with higher potassium excretion. Test for interaction
of higher sodium excretion (above the median) and
potassium excretion was significant (P=0.007) but for
lower sodium excretion and potassium excretion was
not significant (P=0.94).

Sodium excretion and diet quality (mAHEI)
Figure 5 and table 3 report a stratified analysis by
mAHEI thirds, which suggest a lower magnitude of risk
for the association of sodium excretion with mortality
and cardiovascular events among those with higher
diet quality scores, although P for interactions were
not significant (P=0.87 for below median excretion
and P=0.30 above median excretion).

Table 1 | Association of estimated urinary sodium excretion with mortality and cardiovascular events. Values are hazard ratios (95% confidence
intervals)
Estimated sodium excretion (g/day)
Variables
No of deaths and cardiovascular events
Univariate*
Multivariable (primary)†
Multivariable (+diet)
Multivariable (+blood pressure/heart
rate)
Multivariable‡ (excluding CVD, diabetes,
smoker, and cancer)§
Multivariable‡ (excluding events in first
3 years)
Multivariable‡ (primary+lipids)

<3 (n=11 002)
949
1.23 (1.14 to 1.34)
1.19 (1.09 to 1.30)
1.16 (1.05 to 1.27)
1.15 (1.04 to 1.28)

3-3.99 (n=21 417)
1562
1.05 (0.98 to 1.12)
1.06 (0.99 to 1.14)
1.06 (0.98 to 1.14)
1.06 (0.98 to 1.14)

4-4.99 (n=26 012)
1816
1.00
1.00
1.00
1.00

5-5.99 (n=21 093)
1640
1.09 (1.02 to 1.17)
1.08 (1.00 to 1.16)
1.09 (1.01 to 1.17)
1.08 (1.00 to 1.16)

6-6.99 (n=12 458)
964
1.07 (0.99 to 1.16)
1.07 (0.98 to 1.16)
1.08 (0.99 to 1.18)
1.06 (0.96 to 1.16)

≥7 (n=11 218)
953
1.16 (1.07 to 1.26)
1.23 (1.12 to 1.34)
1.26 (1.15 to 1.39)
1.17 (1.06 to 1.28)

1.16 (1.03 to 1.31)

1.04 (0.94 to 1.15)

1.00

1.08 (0.98 to 1.19)

1.06 (0.95 to 1.18)

1.12 (0.99 to 1.25)

1.20 (1.07 to 1.33)

1.11 (1.02 to 1.21)

1.00

1.12 (1.03 to 1.21)

1.09 (0.99 to 1.20)

1.17 (1.06 to 1.30)

1.17 (1.06 to 1.29)

1.06 (0.98 to 1.15)

1.00

1.07 (0.99 to 1.16)

1.05 (0.96 to 1.15)

1.24 (1.13 to 1.36)

CVD=cardiovascular disease.
Major cardiovascular events include cardiovascular mortality, myocardial infarction, stroke, and heart failure.
Primary model includes the following covariates at baseline: age, sex, education, alcohol intake, diabetes mellitus, body mass index, a history of cardiovascular events, cancer and chronic
obstructive pulmonary disease, cardiovascular drugs at baseline, HIV, tuberculosis, physical activity level, and smoking status and dosage. Dietary variables: addition of caloric intake, potassium
intake, waist:hip ratio, and modified alternative healthy eating index score. Blood pressure variables: baseline systolic blood pressure and history of hypertension. Low density lipoprotein
cholesterol:high density lipoprotein cholesterol ratio available in 88% of cohort.
*Univariate analysis using Cox proportional hazards model with a random effect for study centre (to address clustering of data) includes 103 200 participants with follow-up data.
†Includes 90% of all participants in univariate model, 10% of participants had missing data for at least one covariate, we did not undertake imputation for missing data.
‡Adjusted for variables in primary model.
§Excludes those with baseline history of cardiovascular disease, diabetes mellitus, current smoking, and cancer (history of or within first year of follow-up).
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major cardiovascular events (1.20, 1.08 to 1.34),
cardiovascular death (odds ratio 1.49, 95% confidence
interval 1.21 to 1.84), and fatal stroke (hazard ratio
1.76, 95% confidence interval 1.28 to 2.41) on
multivariable analysis (table 1, supplementary table
2, fig 1).
Compared with estimated sodium excretion of 4.00
to 4.99 g/day, lower estimated sodium excretion (<3 g/
day) was associated with a greater risk of the primary
composite outcome (hazard ratio 1.19, 95% confidence
interval 1.09 to 1.30), all cause mortality (1.26, 1.12
to 1.41), major cardiovascular events (1.19, 1.06 to
1.33), cardiovascular death (1.35, 1.09 to 1.69), and
stroke (1.24, 1.05 to 1.46); supplementary table 2. No
association was found between sodium excretion and
cancer or cancer mortality (see supplementary table 2).
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2.2
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0
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4

6
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8

Distribution

Estimated 24 hour sodium excretion (g/day)

Hazard ratio

0-2
Range (g)
1534
Total
No of events 94
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2.6

2-3
8060
367

3-4
19 092
766

4-5
23 414
875

5-6
19 022
760

6-7
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251
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2470
109
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54

Major cardiovascular disease
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1.8
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0

2

4

6
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Distribution

Estimated 24 hour sodium excretion (g/day)

0-2
Range (g)
1534
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No of events 75

2-3
8060
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4-5
23 414
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5-6
19 022
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6-7
11 326
594

7-8
5582
331

8-9
2470
150

9-10
1131
68

Fig 1 | Restricted cubic spline plot of association of estimated 24 hour urinary sodium excretion with composite
of all cause mortality and major cardiovascular events, mortality, and major cardiovascular events (composite of
cardiovascular death or myocardial infarction or stroke or heart failure). Plots adjusted for age (included as spline
function), sex, education, current and former alcohol intake (units weekly), diabetes mellitus, body mass index,
physical activity, history of cardiovascular events, use of cardiovascular drugs (blood pressure lowering, statins,
or antidiabetics), history of tuberculosis, cancer, HIV, and current and former smoking. Dashed lines indicate 95%
confidence intervals. Median intake is reference standard (4.9 g/day). Salt approximates 2.5×sodium g/day. Spline
curve was truncated at 10 g/day in all plots
the bmj | BMJ 2019;364:l772 | doi: 10.1136/bmj.l772
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Composite outcome

2.2
1.8
1.4
1.0

0.6
0

1

2

3

4

Distribution

Estimated 24 hour potassium excretion (g/day)

Hazard ratio

Range (g)
Total
No of events

3.0
2.6

0-1
1749
192

1-2
39 814
3107

2-3
43 836
3118

3-4
6849
409

All cause mortality

2.2
1.8
1.4
1.0

0.6
0

1

2

3

4

Distribution

Estimated 24 hour potassium excretion (g/day)

Hazard ratio

Range (g)
Total
No of events

3.0
2.6

0-1
1749
149

1-2
39 814
1823

2-3
43 836
1588

3-4
6849
186

Major cardiovascular disease

2.2
1.8
1.4
1.0

0.6
0

1

2

3

4

Distribution

Estimated 24 hour potassium excretion (g/day)

Range (g)
Total
No of events

0-1
1749
81

1-2
39 814
1907

2-3
43 836
2094

3-4
6849
291

Fig 2 | Restricted cubic spline plot of association of estimated 24 hour urinary potassium excretion with composite
of all cause mortality and major cardiovascular events, mortality, and major cardiovascular events (composite of
cardiovascular death, myocardial infarction, stroke, and heart failure). Plots adjusted for age (included as spline
function), sex, education, current and former alcohol intake (units weekly), diabetes mellitus, body mass index,
physical activity, history of cardiovascular events, use of cardiovascular drugs (blood pressure lowering, statins, or
antidiabetics), history of tuberculosis, cancer, HIV, and current and former smoking. Spline was truncated at 4 g/day
in all plots
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Estimated sodium excretion (g/day)
Estimated potassium excretion (g/day)
<median, 2.1 g/day:
Hazard ratio (95% CI)
Event proportion*
≥median, 2.1 g/day:
Hazard ratio (95% CI)
Event proportion*

<3

3-5

>5

1.23 (1.11 to 1.37)
716/7582 (9.4%)

1.10 (1.01 to 1.19)
1924/24741 (7.8%)

1.21 (1.11 to 1.32)
1260/14259 (8.8%)

1.19 (1.02 to 1.38)
233/3420 (6.8%)

1.00 (reference)
1454/22 688 (6.4%)

1.10 (1.02 to 1.18)
2297/30 510 (7.5%)

Adjusted for age (included as spline function), sex, education, current and former alcohol intake (units weekly), diabetes mellitus, body mass index,
physical activity, history of cardiovascular events, use of cardiovascular drugs (blood pressure lowering, statins, or antidiabetics), history of tuberculosis,
cancer, HIV, and current and former smoking.
*Event proportion for composite outcome of major cardiovascular events or mortality.

Sensitivity analyses
Exclusion of participants who had events in the first
three years of follow-up, and excluding those with
baseline cardiovascular disease, cancer (or cancer in first
year of follow-up, diabetes, and current smoking), did
not materially affect findings. (table 1) Supplementary
figure 1 reports the association of “usual” 24 hour
urinary sodium excretion and clinical outcomes.
Discussion
In this large international prospective cohort study, we
investigated the joint association of estimated sodium
and potassium urinary excretion (surrogates for intake)
and clinical outcomes over a median follow-up of 8.2
years. Overall, the lowest risk of death and adverse
clinical events was seen in those with estimated sodium
excretion between 3 and 5 g/day, and with the highest

Estimated 24 hour potassium excretion (g/day)

Hazard ratio
1.2 1.1 1.0 0.9

0.8

4

3

2

1

0

0

2.5

5.0

7.5

10.0

Estimated 24 hour sodium excretion (g/day)

Fig 3 | Heat map of risk for composite of cardiovascular events or death showing lowest
risk in region of moderate sodium intake 3-5 g/day and higher potassium intake and
highest risk in region of extremes of sodium excretion and low potassium excretion. The
reference hazard for these hazard ratios was set at a value of sodium daily excretion/
intake of 5.00 g and potassium daily excretion/intake of 2.25 g (median excretion of
sodium and potassium), marked as X. The overlaid lines represent joint distribution
quartiles; each region contains a quarter of the analysed participants. r=0.34
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potassium excretions (see fig 1 and table 2). Both
higher and lower levels of estimated sodium excretion
were associated with higher cardiovascular risk,
thereby describing a J-shaped curve for association,
whereas the association of potassium excretion and
mortality or cardiovascular risk was inverse and linear.
Higher potassium intake attenuated the increased
cardiovascular risk associated with high sodium
intake, and the association of high sodium excretion
with cardiovascular risk was most prominent in those
with low potassium intake.

Comparison with other studies
Potassium, the most abundant intracellular cation,
and sodium, the most abundant extracellular cation,
are inextricably linked, with their exchange required
for membrane potential of cells (Na-K-ATPase) and
their inter-reliance on diet and kidneys to maintain
homeostasis.23 We found that the association
of higher sodium excretion with cardiovascular
risk was lower among those with higher urinary
potassium excretion. While previous studies have
reported that higher potassium intake diminishes the
association of higher sodium intake with increased
blood pressure, no study has been sufficiently large
to show a statistically significant modifying effect of
sodium and potassium intake with cardiovascular
events and mortality.19-24 In our analyses, extremes
of sodium excretion (both high and low) in a setting
of low potassium excretion are associated with the
highest risk of death and cardiovascular events (see
fig 1 and table 2). Low potassium intake not only
results in potassium retention by the kidneys, but also
induces sodium retention.36 37 Renal conservation
of sodium in the setting of low potassium diets is
mediated through WNK (“with no lysine(K)”) kinases
activating the thiazide sensitive sodium-chloride
cotransporter, leading to greater increases in blood
pressure with increasing sodium intake.38 39 Low
potassium intake might also reflect poorer diet quality,
particularly lower intake of fruits and vegetables, and
the association of sodium intake with cardiovascular
risk might be confounded by foods that independently
affect cardiovascular risk. Our subgroup analysis
by diet quality (modified alternative healthy eating
index, mAHEI) would lend some support to this
contention, whereby the magnitude of association of
sodium excretion with cardiovascular risk appeared
7
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Table 2 | Association of joint urinary sodium and potassium excretion with mortality and cardiovascular events

RESEARCH

Estimated sodium excretion (g/day)
Tertiles
<3 (n=11 002)
Potassium excretion (g/day):
<1.8
1.14 (1.00 to 1.30)

3-3.99 (n=21 417)

4-4.99 (n=26 012)

5-5.99 (n=21 093)

6-6.99 (n=12 458)

≥7 (n=11 218)

P for interaction

1.02 (0.91 to 1.14)

1.00

1.02 (0.89 to 1.16)

1.15 (0.97 to 1.36)

1.27 (1.04 to 1.54)

1.8-2.3
1.16 (0.97 to 1.38)
1.11 (0.97 to 1.26)
>2.3
1.12 (0.91 to 1.39)
1.02 (0.88 to 1.18)
Modified alternative healthy eating index score:
<31.3
1.18 (1.01 to 1.38)
1.10 (0.97 to 1.25)

1.00
1.00

1.16 (1.03 to 1.31)
1.08 (0.95 to 1.22)

1.17 (1.01 to 1.36)
1.01 (0.88 to 1.16)

1.47 (1.26 to 1.71)
1.11 (0.96 to 1.27)

P=0.93 (<median
sodium excretion)
P=0.007 (>median
sodium excretion)

1.00

1.11 (0.98 to 1.25)

1.07 (0.92 to 1.25)

1.47 (1.26 to 1.73)

31.3-38.4
>38.4

1.00
1.00

1.14 (1.01 to 1.30)
1.00 (0.88 to 1.14)

1.12 (0.97 to 1.30)
0.99 (0.85 to 1.14)

1.22 (1.05 to 1.43)
1.06 (0.91 to 1.23)

1.24 (1.06 to 1.46)
1.09 (0.92 to 1.29)

1.09 (0.96 to 1.25)
1.03 (0.90 to 1.17)

P=0.87 (<median
sodium excretion)
P=0.30 (>median
sodium excretion)

Adjusted for age (included as spline function), sex, education, current and former alcohol intake (units per week), diabetes mellitus, body mass index, physical activity, history of cardiovascular
events, use of cardiovascular medications (blood pressure lowering, statins, or antidiabetics), history of tuberculosis, cancer, HIV, and current and former smoking.

lower among those consuming the highest third of
diet quality, although formal tests of interaction were
not statistically significant (table 3). Therefore, higher
potassium intake could directly affect cardiovascular
and mortality risks or is a marker of increased intake
of healthier food items that are rich in potassium (eg,
fruit, vegetables, nuts), or a combination of both. The
DASH-Sodium trial reported a lower antihypertensive
effect of reducing sodium intake, in the setting of
higher potassium intake, supporting the contention
that the association of higher sodium intake with
cardiovascular health might be modified by potassium
intake.40 A small cluster randomised controlled
trial (five centres), which replaced table salt with
low sodium salt substitute (partially replaced with
potassium chloride) reported a reduced cardiovascular
risk in those centres randomised to salt substitution,
although findings were not conclusive owing to
methodological limitations of the trial.41 An ongoing
large cluster randomised controlled trial in China,
evaluating the use of salt substitutes (potassium
chloride substituted for sodium chloride) is expected
to provide a more definitive answer.42 However, these
trials evaluate simultaneous increased potassium
intake with a reduction of high sodium intake to
moderate intake levels, and it is unlikely to inform
whether a very low sodium intake (<2.0 g/day) is
beneficial or harmful. Finally, increased cardiovascular
risk might also be mediated through activation
of numerous adaptive renal and neuroendocrine
mechanisms to maintain balance of both electrolytes,
in response to low potassium and low dietary sodium,
especially activation of the renin-aldosteroneangiotensin system,18 the activation of which is
known to increase cardiovascular risk. Collectively,
these data suggest that the health impact of these two
cations cannot be easily assessed separately. However,
our findings would argue against an isolated use of
a sodium:potassium ratio, because of the J-shaped
association of sodium intake and clinical outcomes
and the ratio does not take account of absolute intake
levels. For example, the combination of moderate
8

intake of sodium and potassium is associated with
lower cardiovascular risk than combined low intake
of both sodium and potassium, despite the same
sodium:potassium ratio.

Public health implications
Guidelines for dietary recommendations, targeting the
entire population, should be both feasible and based
on clear high quality evidence of improved health
outcomes.45 Our results suggest that a combined
strategy of low sodium intake (<2.0 g/day), while
simultaneously increasing potassium intake to >3.5 g/
day, is unrealistic, as only 0.002% of the population
were in this range (0.2% for potassium excretion of
2.62 g/day, if we assume that about 75% of potassium
is excreted in urine35). These estimates are consistent
with reports from studies in the United Kingdom
(0.1%), United States (0.3%), Mexico (0.15%), and
France (0.5%).7 In each of these studies, estimates of
sodium intake were based on questionnaire, which
is known to underestimate intake, meaning that the
proportion of the population achieving actual target
may be lower than reported.7 This finding also meant
that we were unable to evaluate the association of
these joint dietary intake levels with health outcomes,
as numbers of participants were insufficient despite
the large sample size. We observed a linear relation
between increased sodium and potassium intake, a
consistent finding of other studies.7 20 These findings
question the feasibility of increasing potassium intake
while achieving very low sodium intake of populations
through modifying diets. While small phase II clinical
trials, such as DASH-Sodium,40 have achieved these
targets in the short term, they required complete
control of dietary intake, which is impractical in free
living populations. In contrast, the PREDIMED study,43
which promoted increased intake of potassium
containing foods (fruit, vegetables, nuts) with
greater adherence to the Mediterranean diet, without
focusing on low sodium intake, reported a statistically
significant reduction in cardiovascular disease and
mortality, and adherence to a Mediterranean diet has
doi: 10.1136/bmj.l772 | BMJ 2019;364:l772 | the bmj
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Table 3 | Association of estimated urinary sodium excretion with mortality and cardiovascular events (subgroup analysis). Values are hazard ratio (95%
confidence interval)
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Potassium <1.8 g/day

2.2
1.8
1.4
1.0

0.6
0

2

4

6

10

8

Distribution

Estimated 24 hour sodium excretion (g/day)

Hazard ratio

Range (g)
Total
No of events

3.0
2.6

0-2
896
87

2-3
4299
352

3-4
8251
631

4-5
7653
577

5-6
4526
362

6-7
2051
185

7-8
838
84

8-9
354
30

9-10
152
19

Potassium 1.8-2.3 g/day

2.2
1.8
1.4
1.0

0.6
0

2

4

6

10

8

Distribution

Estimated 24 hour sodium excretion (g/day)

Hazard ratio

Range (g)
Total
No of events

3.0
2.6

0-2
458
31

2-3
2402
159

3-4
6342
435

4-5
8121
527

5-6
6686
544

6-7
3596
291

7-8
1667
161

8-9
669
64

9-10
277
34

Potassium >2.3 g/day

2.2
1.8
1.4
1.0

0.6
0

2

4

6

8

10

Distribution

Estimated 24 hour sodium excretion (g/day)

Range (g)
Total
No of events

0-2
180
16

2-3
1359
92

3-4
4499
272

4-5
7640
479

5-6
7810
541

6-7
5679
396

7-8
3077
230

8-9
1447
118

9-10
702
52

Fig 4 | Association of urinary sodium excretion within tertiles of urinary potassium excretion. P for interaction is
significant (P=0.007) for urinary potassium excretion×urinary sodium excretion above median intake, with lower
magnitude of association with higher urinary potassium excretion. Plots adjusted for age (included as spline
function), sex, education, current and former alcohol intake (units weekly), diabetes mellitus, body mass index,
physical activity, history of cardiovascular events, use of cardiovascular drugs (blood pressure lowering, statins, or
antidiabetics), history of tuberculosis, cancer, HIV, and current and former smoking
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3.0
2.6

mAHEI score <31.3

2.2
1.8
1.4
1.0

0.6
0

2

4

6

10

8

Distribution

Estimated 24 hour sodium excretion (g/day)

Hazard ratio

Range (g)
Total
No of events

3.0
2.6

0-2
445
42

2-3
2640
194

3-4
6400
468

4-5
7792
517

5-6
5972
480

6-7
3272
250

7-8
1461
137

8-9
621
66

9-10
251
24

mAHEI score 31.3-38.4

2.2
1.8
1.4
1.0

0.6
0

2

4

6

10

8

Distribution

Estimated 24 hour sodium excretion (g/day)

Hazard ratio

Range (g)
Total
No of events

3.0
2.6

0-2
413
43

2-3
2346
185

3-4
5742
415

4-5
7291
491

5-6
6132
477

6-7
3708
293

7-8
1811
151

8-9
802
69

9-10
398
43

mAHEI score >38.4

2.2
1.8
1.4
1.0

0.6
0

2

4

6

8

10

Distribution

Estimated 24 hour sodium excretion (g/day)

Range (g)
Total
No of events

0-2
531
34

2-3
2467
174

3-4
5746
385

4-5
7100
497

5-6
6120
441

6-7
3951
294

7-8
2100
169

8-9
978
70

9-10
454
35

Fig 5 | Association of urinary sodium excretion within tertiles of modified alternative healthy eating index (mAHEI)
score. P for interactions not significant. Plots adjusted for age (included as spline function), sex, education,
current and former alcohol intake (units weekly), diabetes mellitus, body mass index, physical activity, history of
cardiovascular events, use of cardiovascular drugs (blood pressure lowering, statins, or antidiabetics), history of
tuberculosis, cancer, HIV, and current and former smoking
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Strengths and limitations of this study
Our estimate of sodium intake was based on a baseline
measurement of sodium intake, derived from fasting
morning urine samples, rather than repeated 24 hour
urinary collections, which would be considered the
reference standard for estimating usual sodium and
potassium intake. However, our approach has been
validated in an international study, against actual
24 hour urine estimates of sodium and potassium
excretion.31 Other formula based approaches have
been developed for estimating 24 hour urinary sodium
and potassium excretion, and one study reported that
the Kawasaki formula was associated with the largest
bias compared with actual 24 hour urine collections.
In that study by Cogswell et al,47 however, a nonfasting spot urine sample was used, which would be
expected to produce biased over-estimates since the
Kawasaki formula was developed and validated for a
fasting urine sample, best reflecting basal excretion.
In another study,48 which used an appropriate fasting
sample, the Kawasaki formula approach was reported
to be associated with least biased estimates (versus
other formula) compared with actual 24 hour urine.
Further evidence of the construct validity of our
approach is the relation of estimated 24 hour urine
estimates of sodium excretion to blood pressure
(2.11/0.78 mm Hg/g increase in estimated 24 hour
urinary sodium excretion), which are consistent with
estimates reported in randomised controlled trials of
sodium reduction.25
Relating a single time-point estimate of sodium and
potassium intake to long term follow-up of death and
cardiovascular events might be problematic if there are
interval changes in dietary intake over time, and where
repeated dietary measures are required to reduce
the risk of regression dilution bias. Our approach is
consistent with many other large epidemiological
studies of sodium and potassium intake and analogous
to epidemiological studies relating blood pressure,
glucose, and cholesterol to clinical outcomes. For
example, the correlation of office blood pressure and
24 hour ambulatory blood pressure and of fasting
glucose to glycated haemoglobin (HbA1c), is similar
to the correlation we report for formula derived
estimates.31 We chose this practical approach to
estimating population level sodium and potassium
intake in the PURE study, which includes a large
representative population of participants from high,
the bmj | BMJ 2019;364:l772 | doi: 10.1136/bmj.l772

middle, and low income countries. We deemed
actual 24 hour collections to be unfeasible in many
low income settings and expected to have a greater
risk selection bias due to non-completion of 24 hour
collections. For example, in a recent NHANES study,49
completion rates for 24 hour urine samples were about
75%, and completers differed from non-completed for
age, sex, ethnicity, body mass index, and hypertension
status. For these reasons, WHO suggests50 the use of
formula derived estimates of sodium and potassium
intake in population level studies monitoring intakes
over time. Among studies reporting on temporal
changes of sodium intake over time, there is stability
in mean intake of countries,6 51 especially those with
mean sodium intake in the moderate range (3-5 g/day),
whereas some countries with high mean intakes (>5 g/
day) have reported reductions in mean intake levels
(eg, China, Finland),52 which means that interval
changes in sodium intake are less likely to influence
our findings in the low to moderate range of sodium
intake but could reduce the magnitude of association
in the higher sodium intake range.
Reverse causation has been a criticism of
prospective cohort studies evaluating the association
of diet and clinical outcomes, which may also occur
when people reduce their sodium intake because
of illness or based on medical recommendations.
Alternatively, it may occur when people with a history
of cardiovascular disease or risk factors, who are at
increased cardiovascular risk, reduce their sodium
intake on medical recommendations. In the PURE
study, a few participants had previous cardiovascular
disease, and our findings were not materially altered
with their exclusion. Moreover, in the current analyses
the exclusion of participants with cancer or diabetes
or who were current smokers or those who had events
in the first three years of follow-up did not materially
alter findings. Additionally, we did not find an
increased risk of death due to cancer with low sodium
intake. Finally, given the observational nature of the
study, residual confounding is a potential limitation.
However, we adjusted for all major confounders of the
association between sodium and potassium intake and
cardiovascular events. Strengths of our study include
the large representative international population in
the PURE study, completeness of follow-up, rigorous
approach to measurement of baseline variables, and
adjudicated outcome clinical events.

Conclusions
Our findings suggest that a simultaneous target of low
sodium (<2 g/day) with high potassium intake (>3.5
g/day) in the population is extremely uncommon.
The combination of moderate sodium intake (3-5 g/
day) with high potassium intake is associated with
the lowest risk of mortality and cardiovascular events,
whereas extremes of sodium intake combined with
low potassium urinary excretion were associated with
the highest cardiovascular risk. Our data support
population wide increases in dietary potassium intake,
with a population specific (ie, sodium intakes >5 g/
11
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an inconsistent correlation with sodium intake.44 45
In addition, a recent analysis of the NHANES study
reported that sodium intake >2.3 g/day was associated
with better diet quality, compared with diets of less
than 2.3 g/day, meaning that improving dietary quality
is likely to be easier to achieve within a moderate
sodium intake range.46 These considerations raise
considerable doubts about the feasibility and assumed
cardiovascular effects of current recommendations to
reduce sodium intake to very low levels (<2 g/day),
which may counteract achieving other dietary targets
and improving overall dietary quality.
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day) reduction of sodium intake, embedded within an
overall healthy dietary pattern.
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